185 related articles for article (PubMed ID: 8350627)
1. Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model.
Gravatt LC; Chaffee S; Hebert ME; Halperin EC; Friedman HS; Kurtzberg J
Leukemia; 1993 Aug; 7(8):1261-7. PubMed ID: 8350627
[TBL] [Abstract][Full Text] [Related]
2. Guanine arabinoside as a bone marrow-purging agent.
Kurtzberg J
Ann N Y Acad Sci; 1993 Jun; 685():225-36. PubMed ID: 8363226
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine.
Hebert ME; Greenberg ML; Chaffee S; Gravatt L; Hershfield MS; Elion GB; Kurtzberg J
Transplantation; 1991 Oct; 52(4):634-40. PubMed ID: 1926342
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant deoxycytidine levels are high enough to profoundly alter 9-beta-D-arabinofuranosylguanine cytotoxicity for human T-cell acute leukemia cells in vitro.
Cohen JD; Strock DJ; Teik JE; LaGuardia EA; Katz TB
Pediatr Hematol Oncol; 1999; 16(3):239-44. PubMed ID: 10326222
[TBL] [Abstract][Full Text] [Related]
5. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
Kühl JS; Sikic BI; Blume KG; Chao NJ
Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model.
Wang E; Conant JM; Li D; Visconti V; Chourmouzis E; Lau C
Bone Marrow Transplant; 1990 Oct; 6(4):235-42. PubMed ID: 2085697
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
8. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.
Shewach DS; Mitchell BS
Cancer Res; 1989 Dec; 49(23):6498-502. PubMed ID: 2819707
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging.
Gautam SC; Xu YX; Dumaguin M; Janakiraman N; Chapman RA
Bone Marrow Transplant; 2000 Mar; 25(6):639-45. PubMed ID: 10734298
[TBL] [Abstract][Full Text] [Related]
10. [Establishment and application of a murine transplant model of bone marrow purging of metastatic breast cancer cells in vitro].
Hu ZP; Liu WL; Stuart B; Zhang YC
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):621-3. PubMed ID: 18246821
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103
[TBL] [Abstract][Full Text] [Related]
12. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
13. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(3):144-54. PubMed ID: 10392960
[TBL] [Abstract][Full Text] [Related]
14. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
Waller EK; Giver CR; Rosenthal H; Somani J; Langston AA; Lonial S; Roback JD; Li JM; Hossain MS; Redei I
Blood Cells Mol Dis; 2004; 33(3):233-7. PubMed ID: 15528137
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
[TBL] [Abstract][Full Text] [Related]
16. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
18. Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells.
Curbo S; Zhu C; Johansson M; Balzarini J; Karlsson A
Biochem Biophys Res Commun; 2001 Jul; 285(1):40-5. PubMed ID: 11437369
[TBL] [Abstract][Full Text] [Related]
19. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow transplantation for leukemia.
Stuart RK
Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
